172 related articles for article (PubMed ID: 28302759)
1. Preclinical Evaluation of
Piert M; Shao X; Raffel D; Davenport MS; Montgomery J; Kunju LP; Hockley BG; Siddiqui J; Scott PJH; Chinnaiyan AM; Rajendiran T
J Nucl Med; 2017 Aug; 58(8):1216-1223. PubMed ID: 28302759
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
3. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
[TBL] [Abstract][Full Text] [Related]
4. Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.
Heger Z; Gumulec J; Cernei N; Polanska H; Raudenska M; Masarik M; Eckschlager T; Stiborova M; Adam V; Kizek R
Prostate; 2016 May; 76(7):679-90. PubMed ID: 26847870
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
[TBL] [Abstract][Full Text] [Related]
8. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Sreekumar A; Poisson LM; Rajendiran TM; Khan AP; Cao Q; Yu J; Laxman B; Mehra R; Lonigro RJ; Li Y; Nyati MK; Ahsan A; Kalyana-Sundaram S; Han B; Cao X; Byun J; Omenn GS; Ghosh D; Pennathur S; Alexander DC; Berger A; Shuster JR; Wei JT; Varambally S; Beecher C; Chinnaiyan AM
Nature; 2009 Feb; 457(7231):910-4. PubMed ID: 19212411
[TBL] [Abstract][Full Text] [Related]
12. Choline transporter as a novel target for molecular imaging of cancer.
Hara T; Bansal A; DeGrado TR
Mol Imaging; 2006; 5(4):498-509. PubMed ID: 17150162
[TBL] [Abstract][Full Text] [Related]
13. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
[TBL] [Abstract][Full Text] [Related]
14. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer--a large nested case-control study within the JANUS cohort in Norway.
de Vogel S; Ulvik A; Meyer K; Ueland PM; Nygård O; Vollset SE; Tell GS; Gregory JF; Tretli S; Bjørge T
Int J Cancer; 2014 Jan; 134(1):197-206. PubMed ID: 23797698
[TBL] [Abstract][Full Text] [Related]
15. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
[TBL] [Abstract][Full Text] [Related]
18. Imaging prostate cancer with 11C-choline PET/CT.
Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
[TBL] [Abstract][Full Text] [Related]
19. Prospective head-to-head comparison of
Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
[TBL] [Abstract][Full Text] [Related]
20. SNAT2 is responsible for hyperosmotic induced sarcosine and glycine uptake in human prostate PC-3 cells.
Nielsen CU; Krog NF; Sjekirica I; Nielsen SS; Pedersen ML
Pflugers Arch; 2022 Dec; 474(12):1249-1262. PubMed ID: 36175560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
